UnknownPhase 2

A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML

60 participantsStarted 2023-02

Plain-language summary

This is a randomized, double-blinded, Phase 2 trial in patients with PML due to JCPyV. Patients will receive treatment with a matched virus-specific T-cell product (CE VST01-JC) or placebo, and will then be monitored for response to therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

* Male or female subjects aged 18 years or older, with actively progressing PML confirmed by MRI and JCPyV present in CSF or in brain biopsy tissue (diagnosis confirmed according to algorithm diagnostic criteria for PML developed by the American Academy of Neurology).

What they're measuring

To evaluate the effect of CE-VST01-JC on time to disease progression, as measured by mRS (modified Rankin Score)

Timeframe: 1 year

Trial details

NCT IDNCT05541549

SponsorCellevolve Bio Inc

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-03

View on ClinicalTrials.gov More Progressive Multifocal Leukoencephalopathy trials